FDA Asks Health Care Professionals to Reduce Acetaminophen Doses

Aimee Simone, Assistant Editor
Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
The agency has asked prescribers not to prescribe medications containing more than 325 mg of acetaminophen per dose.

The FDA has asked health care professionals to stop prescribing and dispensing prescription painkillers that contain more than 325 milligrams of acetaminophen per tablet, due to concerns regarding potential liver damage.
 
In a warning released on January 14, 2014, the agency asserted that the benefits of taking combination products containing more than 325 mg of acetaminophen do not outweigh the risks for serious liver damage. With the new recommendation, the FDA also hopes to reduce the occurrence of accidental acetaminophen overdoses, which can cause liver failure and death. Severe liver injury has also occurred in patients who simultaneously took multiple products containing acetaminophen and in those who consumed alcohol while taking acetaminophen medications.
 
The FDA also requested that pharmacists play a role in helping to prevent liver damage caused by acetaminophen products. The warning suggests that when pharmacists receive a prescription for combination products containing more than 325 mg of acetaminophen, they should contact the prescriber and recommend a product with a smaller dose of the drug. When appropriate, a 2-tablet dose is still acceptable, for a total dose of 650 mg of acetaminophen.
 
In January 2011, the FDA asked drug manufacturers to limit the amount of acetaminophen in products that contain the drug to 325 mg. The FDA requested that these limitations to acetaminophen be made by January 14, 2014. More than half of manufacturers voluntarily agreed to limit the amount of acetaminophen in their products, but some prescription products containing more than the recommended amount of the drug are still available. The warning notes that the agency plans to take steps to withdraw approval of combination products that contain high amounts of acetaminophen per dose.
 
The warning does not apply to over-the-counter products containing acetaminophen, and notes that these products will be addressed in a future regulatory action.
Related Articles
I distinctly remember feeling surprised when the FDA approved the first single entity and extended-release hydrocodone pain medication.
Are pharmacists fully aware of the warnings associated with the medications they dispense?
Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.
Most people hear “hospice” and think “cancer,” but many end-stage chronic obstructive pulmonary disease patients also receive hospice care when their caregivers can no longer provide the medical attention they need.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$